Group items tagged

'Curing aging is not an endpoint the federal drug agency would recognize,' Dr. Westphal says dryly. Instead, both men say, they are working to ameliorate the diseases of aging." For so long as unelected government employees can declare, with no accountability and full force of law, what medicine is permitted and what is not, there will be no direct venture funded efforts to cure aging - or even to take the first steps by aiming to repair specific, identified age-related damage in order to intervene in the aging process. There is no lack of companies, research groups and billions of dollars ready to be directed to that end, as any brief survey of the biotechnology marketplace will show you - but the ignorant few who write policy continue to bury all that potential.

It was Dr. Shock's insistence on answering what he considered the discipline's two critical questions that made an impact on the field of gerontology: "What are the underlying biological factors that produce what we perceive as aging?" and, "What are the mechanisms that produce impaired performance with age?" For aging, he insisted, was not a disease.

Nathan Wetherell Shock, Ph.D. began his gerontology career in 1941 as the chief of the newly formed Unit on Gerontology of the Division of Physiology of the five-year-old National Institute of Health. He took this two-man aging unit and built it into the internationally respected Gerontology Research Center of the National Institute on Aging, NIH. Dr. Shock was the catalyst for the emergence of aging research in the United States and overseas for nearly half a century.

The central focus of our research is understanding age-related changes in physiology and the ability to adapt to environmental stress. This understanding is then applied to developing insight about the pathophysiology of age-related diseases. The program seeks to understand the changes associated with healthy aging and to define the criteria for evaluating when a change becomes pathologic.

The National Institute on Aging (NIA) is a division of the U.S. National Institutes of Health (NIH), located in Bethesda, Maryland. The NIA leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. In 1974, Congress granted authority to form NIA to provide leadership in aging research, training, health information dissemination, and other programs relevant to aging and older people. Subsequent amendments to this legislation designated the NIA as the primary Federal agency on Alzheimer's disease research.

Welcome to the Department of Health and Ageing

Division of Aging Biology (DAB)Supports research and training to enhance and extend the human health span through a better understanding of the biological mechanisms underlying the aging process.  

Division of Geriatrics and Clinical Gerontology (DGCG)Supports research on health and disease in the aged and research on aging over the human lifespan, including its relationships to health outcomes.

Dr. Miller formerly led business operations for the global Drug Discovery Division at pharmaceutical company Glaxo Smith Kline.

Well one thing that I think is going to be critical is that in the past, pharmaceutical companies had treated diseases of aging as discrete entities, that is to develop something for diabetes, to develop something for osteoporosis…that is to treat each one as a separate silo if you will.

in the future we are going to have to look at more central regulatory pathways that are being identified now for aging.